GLP-1 telehealth ads: what '24-hour approval' actually means

What did @philsmypharmacist actually say?

The creator, who identifies as a pharmacist, made three core claims: that Ozempic produces roughly 17% weight loss, that Mounjaro (tirzepatide) gets you "22%," and that taking GLP-1 medications alone "won't work" for keeping weight off long-term. He also promoted Oak Longevity's program, which bundles prescribers, nutritionists, compounded GLP-1 products, and potency and sterility testing.

He framed this in the context of his own $100,000 investment in a clean room, suggesting he has professional skin in the compounding game. That context matters. He's not a neutral observer, and the audience should know that before taking his product quality claims at face value.

Does the science back this up?

The weight loss numbers he cited are roughly accurate, though he rounds generously. The SUSTAIN 6 and STEP 1 trials for semaglutide showed average body weight reductions of around 14-15% at 68 weeks, not quite the 17% he claims. Tirzepatide data is stronger.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that tirzepatide 15mg produced a mean weight reduction of 20.9% over 72 weeks, with some participants exceeding 22%. So his "22%" figure isn't fabricated, but it represents near-best-case outcomes at the highest dose. The average is closer to 16-21% depending on dose. Citing the ceiling as the headline number is a well-worn marketing move.

His claim that GLP-1 alone leads to failure is supported by relapse data. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that patients who stopped semaglutide regained about two-thirds of lost weight within a year. Behavioral and dietary support improves durability.

What did they get wrong (or right)?

He got the directional science right but inflated the headline numbers. Calling tirzepatide a "22%" drug without qualification oversells it. The SURMOUNT-1 mean was closer to 21% at max dose, and real-world outcomes consistently run lower than clinical trial averages.

His point that "if you're just getting GLP-1 medications in order to lose that 22%, won't work" when you come off is actually one of the more honest things said in this video. Obesity is a chronic condition, and discontinuation leads to regrowth for most people. The BUILD trial and STEP extension data both support this.

Where he gets murkier is the compounding pitch. He says Oak Longevity does "potency sterility studies" and that they "stand behind what they sell." These are unverifiable claims in a 60-second TikTok. Compounded semaglutide and tirzepatide are not FDA-approved products, and compounded versions are not equivalent to brand-name drugs, full stop. The FDA issued warnings about compounded semaglutide products in 2024, citing dosing errors and adverse events.

What should you actually know?

The weight loss percentages for GLP-1 drugs are real, but they come from highly controlled clinical trials with consistent dosing, monitoring, and often behavioral support built in. Real-world numbers at six and twelve months tend to fall below trial peaks.

Compounded GLP-1 medications entered a legal gray zone after the FDA placed both semaglutide and tirzepatide on its shortage list. As of early 2025, the FDA has declared the shortage resolved for tirzepatide and is moving toward the same for semaglutide, which means compounding pharmacies will face stricter limits. Products from 503A and 503B compounders vary in quality, and no compounded GLP-1 product has gone through the same approval process as Ozempic, Wegovy, Mounjaro, or Zepbound.

That does not mean every compounded product is dangerous. It means you cannot assume equivalency, and you should ask hard questions about the pharmacy's 503B accreditation status before agreeing to treatment.

• Always ask if the compounding pharmacy is 503A or 503B registered.
• Request certificates of analysis for potency and sterility, not just verbal assurances.
• Understand that "approved within 24 hours" telehealth models vary widely in clinical thoroughness.
• Long-term GLP-1 use requires ongoing monitoring, not just a one-time prescription.